Eva Carrasco

Eva Carrasco

UNVERIFIED PROFILE

Are you Eva Carrasco?   Register this Author

Register author
Eva Carrasco

Eva Carrasco

Publications by authors named "Eva Carrasco"

Are you Eva Carrasco?   Register this Author

48Publications

2429Reads

45Profile Views

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.

Eur J Cancer 2019 Oct 4;120:54-64. Epub 2019 Sep 4.

GEICAM (Grupo GEICAM de Investigación en Cáncer de Mama), Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain; IMIM Hospital del Mar Medical Research Institute; Barcelona, Spain; Medical Oncology Department Hospital del Mar, Barcelona, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.07.003DOI Listing
October 2019

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study.

Invest New Drugs 2019 02 9;37(1):98-108. Epub 2018 Jun 9.

Department of Medical Oncology, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense, Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, C/Dr. Esquerdo 46, 28009, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0614-9DOI Listing
February 2019

Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients.

ESMO Open 2017 3;2(3):e000187. Epub 2017 Aug 3.

European Society for Medical Oncology (ESMO), Clinic of Oncology,University Hospital, Zürich, Zurich, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2017-000187DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634488PMC
August 2017

Physical activity and breast cancer risk by pathological subtype.

Gynecol Oncol 2017 03 3;144(3):577-585. Epub 2017 Jan 3.

Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain; Consortium for Biomedical Research in Epidemiology and Public Health (CIBER Epidemiología y Salud Pública, CIBERESP), Madrid, Spain; Cancer Epidemiology Research Group, Oncology and Hematology Area, IIS Puerta de Hierro (IDIPHIM), Madrid, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2016.12.014DOI Listing
March 2017

Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.

PLoS One 2015 15;10(5):e0126096. Epub 2015 May 15.

Cancer Epidemiology Unit, National Center for Epidemiology, Instituto de Salud Carlos III, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain; Cancer Epidemiology Research Group, IIS Puerta de Hierro (IDIPHIM), Majadahonda, Madrid, Spain.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0126096PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4433351PMC
March 2016

Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.

J Clin Oncol 2015 Nov 28;33(32):3788-95. Epub 2015 Sep 28.

Miguel Martín, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense; Carlos Jara, Fundación Hospitalaria de Alcorcón; Noelia Martínez-Jáñez, Hospital Universitario Ramón y Cajal; César Mendiola Fernández, Hospital Universitario; Ana Isabel Ballesteros, Hospital de la Princesa; Maribel Casas, María del Carmen Cámara, and Eva Carrasco, GEICAM Headquarters, Madrid; Amparo Ruiz Simón, Instituto Valenciano de Oncología; Ana Santaballa, Hospital Universitario La Fe; Ana Lluch, Hospital Clínico Universitario de Valencia-INCLIVA-Universidad de Valencia, Valencia; Manuel Ruiz Borrego, Hospital Universitario Virgen del Rocío, Sevilla; Nuria Ribelles, Hospital Universitario Virgen de la Victoria IBIMA, Málaga; Álvaro Rodríguez-Lescure, Hospital General de Elche; Encarna Adrover, Hospital Clínico Universitario de Alicante, Alicante; Montserrat Muñoz-Mateu, Hospital Clinic i Provincial; Sonia González, Hospital Mutua de Terrassa; Mireia Margelí Vila, Hospital Universitario Germans Trias i Pujol; Agustí Barnadas, Universitat Autònoma de Barcelona, Barcelona; Manuel Ramos, Centro Oncológico de Galicia; Lourdes Calvo, Complejo Hospitalario Universitario A Coruña, A Coruã; Sonia Del Barco Berron, Instituto Catalán de Oncología, Girona; César A. Rodríguez, Hospital Universitario de Salamanca, Salamanca, Spain; Eduardo Martínez de Dueñas, Hospital Provincial de Castellón, Castellón; Raquel Andrés, Hospital Universitario Lozano Blesa, Zaragoza; Arrate Plazaola, Onkologikoa, San Sebastián; Juan de la Haba-Rodríguez, Universidad de Córdoba, Córdoba; Jose Manuel López-Vega, Hospital Universitario Marqués de Valdecilla, Santander; Pedro Sánchez-Rovira, Complejo Hospitalario de Jaén, Jaén; and José M. Baena-Cañada, Hospital Universitario Puerta del Mar, Cádiz, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.61.9510DOI Listing
November 2015

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Oncologist 2015 May 23;20(5):474-82. Epub 2015 Apr 23.

Lineberger Comprehensive Cancer Center and Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, USA; Clinical Trials and Statistics Unit at The Institute of Cancer Research, London, United Kingdom; Servicio de Oncología Médica, Instituto de Investigacion Sanitaria Hospital Universitario Gregorio Marañón, Facultad de Medicina, Universidad Complutense, Madrid, Spain; Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada; Translation Genomics Unit, Vall d´Hebron Institute of Oncology, Barcelona, Spain; British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Department of Medical Oncology, Hospital General Universitario de Elche, Alicante, Spain; Department of Medical Oncology, Instituto Valenciano de Oncologia, Valencia, Spain; National Cancer Institute of Canada Clinical Trials Group, Kingston, Ontario, Canada; Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Seville, Spain; Department of Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain; Department of Medical Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain; GEICAM, Madrid, Spain; Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada; McMaster University, Hamilton, Ontario, Canada; Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Department of Pathology, University of Utah Health Sciences Center, Salt Lake City, Utah, USA; Department of Medicine, Washington University, St. Louis, Missouri, USA; Department of Oncology, Hospital of Prato, Istituto Toscani Tumori, Florence, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2014-0372DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4425383PMC
May 2015

Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study.

J Clin Oncol 2015 Mar 17;33(9):1045-52. Epub 2015 Feb 17.

Miguel Martín, Instituto de Investigación Sanitaria Gregorio Marañón, Universidad Complutense; Noelia Martinez, University Hospital Ramón y Cajal; José Ángel Garcia-Saenz, University Hospital Clínico San Carlos; Eva Carrasco, Grupo Español de Investigación en Cáncer de Mama, Madrid; Serafín Morales, Hospital Arnau de Vilanova de Lérida, Lérida; Angel Guerrero, Valencian Institute of Oncology, Valencia; Antonio Anton, University Hospital Miguel Servet, Zaragoza; Montserrat Muñoz, University Hospital Clinic i Provincial; Mireia Margeli, Hospital Universitario Germans Trias i Pujol, Barcelona; Miguel Gil, Catalan Institute of Oncology, Hospitalet; Manuel Ramos, Centro Oncológico de Galicia, La Coruña; Juan R. De la Haba-Rodriguez, Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC) -Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain; Sibylle Loibl, Gunter von Minckwitz, and Keyur Mehta, German Breast Group, Neu-Isenburg; Sibylle Loibl, Gunter von Minckwitz, and Keyur Mehta, Sana Klinikum Offenbach, Offenbach; Bahriye Aktas, University Women's Hospital Essen, Essen; Winfried Schoenegg, Medical Practice Berlin, Berlin; Cornelia Liedtke, University Women's Hospital Münster, Münster; Cornelia Liedtke, University Hospital Lübeck, Lübeck; and Grischa Wachsmann, Klinikum Böblingen, Böblingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.2388DOI Listing
March 2015

Regional and seasonal influence in patient's toxicity to adjuvant chemotherapy for early breast cancer.

Breast Cancer Res Treat 2011 Jan 28;125(1):273-8. Epub 2010 Aug 28.

Servicio de Oncología Médica, Hospital Universitario Reina Sofía, Avda Menendez Pidal s/n, 14005 Córdoba, Spain.

View Article

Download full-text PDF

Source
http://link.springer.com/content/pdf/10.1007/s10549-010-1136
Web Search
http://link.springer.com/10.1007/s10549-010-1136-0
Publisher Site
http://dx.doi.org/10.1007/s10549-010-1136-0DOI Listing
January 2011

Lack of effects of pramipexole on REM sleep behavior disorder in Parkinson disease.

Sleep 2008 Oct;31(10):1418-21

Neurology Service, Hospital Clinic, Institut d'Investigació Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2572747PMC
October 2008

Changes in dreaming induced by CPAP in severe obstructive sleep apnea syndrome patients.

J Sleep Res 2006 Dec;15(4):430-6

Neurology Service, Neuroscience Institute, Hospital Clínic i Provincial of Barcelona and Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2869.2006.00553.xDOI Listing
December 2006

Tamoxifen therapy for ovarian cancer in the adjuvant and advanced settings: systematic review of the literature and implications for future research.

Gynecol Oncol 2002 Feb;84(2):201-9

Clinical Research Department, Eli Lilly and Company, Alcobendas, Madrid, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1006/gyno.2001.6489DOI Listing
February 2002